366 related articles for article (PubMed ID: 30620624)
41. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells.
Chen Y; Xu J; Pan W; Xu X; Ma X; Chu Y; Wang L; Pang S; Li Y; Zou B; Zhou G; Gu J
Thorac Cancer; 2022 Jul; 13(13):1961-1973. PubMed ID: 35599381
[TBL] [Abstract][Full Text] [Related]
42. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
43. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
44. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
[TBL] [Abstract][Full Text] [Related]
45. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
[TBL] [Abstract][Full Text] [Related]
46. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
47. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
48. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2
Kumar S; Das S; Sun J; Huang Y; Singh SK; Srivastava P; Sondarva G; Nair RS; Viswakarma N; Ganesh BB; Duan L; Maki CG; Hoskins K; Danciu O; Rana B; Li S; Rana A
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2205454119. PubMed ID: 36095190
[TBL] [Abstract][Full Text] [Related]
49. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
50. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
51. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
52. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
53. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
54. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
55. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
56. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
57. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
58. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
Yang M; Li Y; Kong L; Huang S; He L; Liu P; Mo S; Lu X; Lin X; Xiao Y; Shi D; Huang X; Chen B; Chen X; Ouyang Y; Li J; Lin C; Song L
J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37463446
[TBL] [Abstract][Full Text] [Related]
60. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]